

Riccardo Marconcini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57807/publications.pdf>

Version: 2024-02-01

14
papers

1,027
citations

1039880

9
h-index

1281743

11
g-index

14
all docs

14
docs citations

14
times ranked

2026
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
2	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. British Journal of Cancer, 2018, 118, 820-824.	2.9	190
3	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131
4	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
5	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	1.3	85
6	Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget, 2018, 9, 12452-12470.	0.8	73
7	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. Experimental Hematology and Oncology, 2017, 6, 6.	2.0	38
8	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	3.4	31
9	Anti-PD1 antibodies in patients aged ≥75 years with metastatic melanoma: A retrospective multicentre study. Journal of Geriatric Oncology, 2020, 11, 515-522.	0.5	31
10	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
11	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	2.0	11
12	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	1.3	10
13	Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience. Endocrine, 2021, 74, 707-713.	1.1	8
14	Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.. Journal of Clinical Oncology, 2018, 36, 10038-10038.	0.8	0